Evidence map›Paper›PMID 42714773›Full record

Observational studyEuropean radiology experimental2026

Validating the biological origin of in vivo fractional intracellular volume from VERDICT-MRI in the prostate.

Marta Masramon, Manju Mathew, Saurabh Singh, Thomy Mertzanidou, Joey Clemente, Adam Retter, Natasha Thorley, Adam Phipps, Thomas Parry, Marianti-Vasiliki Papoutsaki and 15 more

Registry-linked trialAbstract readObservational StudyValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in European radiology experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04792138 (Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04792138 unknown statusnot on this map

Learning MRI and Histology Image Mappings for Cancer Diagnosis and Prognosis

TypeobservationalSponsorUniversity College, LondonRan2020 to 2023Enrolled300ConditionsProstate Cancer, Prostate NeoplasmArmsVERDICT MRI, Luminal Index Imaging
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Marta Masramon *Hawkes Institute, UCL, London, UK. rmapasr@ucl.ac.uk.ORCID http://orcid.org/0009-0006-3129-8948
Manju Mathew *Centre for Medical Imaging, UCL, London, UK.
Saurabh SinghCentre for Medical Imaging, UCL, London, UK.
Thomy MertzanidouHawkes Institute, UCL, London, UK.
Joey ClementeCentre for Medical Imaging, UCL, London, UK.
Adam RetterCentre for Medical Imaging, UCL, London, UK.
Natasha ThorleyCentre for Medical Imaging, UCL, London, UK.
Adam PhippsCentre for Medical Imaging, UCL, London, UK.
Thomas ParryCentre for Medical Imaging, UCL, London, UK.
Marianti-Vasiliki PapoutsakiCentre for Medical Imaging, UCL, London, UK.
Lorna SmithInstitute of Cardiovascular Sciences, UCL, London, UK.
Francesco GrussuHawkes Institute, UCL, London, UK.
Veeru KasivisvanathanDivision of Surgery and Interventional Sciences, UCL, London, UK.
Alistair GreyDivision of Surgery and Interventional Sciences, UCL, London, UK.
Eoin DinneenDivision of Surgery and Interventional Sciences, UCL, London, UK.
Greg ShawDivision of Surgery and Interventional Sciences, UCL, London, UK.
Dominic PatelResearch Department of Oncology, UCL, London, UK.
Lucy CaseltonARC Operation and Strategic Development Group, UCL, London, UK.
Caroline M MooreDivision of Surgery and Interventional Sciences, UCL, London, UK.
David AtkinsonCentre for Medical Imaging, UCL, London, UK.
Aiman HaiderDepartment of Pathology, UCLH, London, UK.
Alex FreemanDepartment of Pathology, UCLH, London, UK.
Daniel C AlexanderHawkes Institute, UCL, London, UK.
Shonit Punwani *Centre for Medical Imaging, UCL, London, UK.
Eleftheria Panagiotaki *Hawkes Institute, UCL, London, UK.

Funding

Engineering and Physical Sciences Research Council EP/N021967/1Engineering and Physical Sciences Research Council EP/R006032/1Engineering and Physical Sciences Research Council EP/S021930/1Prostate Cancer UK PG14-018-TR2
6 · The paper itself

Abstract

objectiveNoninvasive microstructure estimates using magnetic resonance imaging (MRI) show potential in improving prostate cancer (PCa) diagnosis; however, histological validation is necessary. MATERIALS AND

methodsWe used data from the Histo-MRI trial (NCT04792138). Participants with biopsy-confirmed PCa underwent multiparametric (mp) MRI and "vascular, extracellular, and restricted diffusion for cytometry in tumors" (VERDICT)-MRI before radical prostatectomy. Personalized molds enabled matching prostatectomy histology with corresponding VERDICT-MRI images. Comparisons between histological epithelial cell density measures and MRI were made on a region-of-interest (ROI) basis using Pearson correlation coefficient (r) with 95% confidence interval (CI). Differences between benign tissue and clinically significant PCa were analyzed using the area under the receiver operating characteristic curve (AUC).

resultsFifty-two participants, aged 65 ± 6 years (mean ± standard deviation), with Gleason grade ≥ 3 + 4, were included. ROI analysis showed stronger correlations of VERDICT fractional intracellular volume (fIC) with epithelial fraction, epithelial cell density, and cell density (r = 0.784 [0.70, 0.84], 0.747 [0.66, 0.81], 0.711 [0.60, 0.79] than VERDICT ADC (r = -0.639 [-0.54, -0.71], -0.609 [-0.51, -0.69], -0.587 [-0.45, -0.69]), or mpMRI ADC (r = -0.357 [-0.18, -0.51], -0.315 [-0.15, -0.46], -0.266 [-0.08, -0.43]), respectively (p < 0.001). VERDICT fIC showed similar differences between benign and clinically significant PCa (0.16 ± 0.10 to 0.51 ± 0.13, AUC = 0.99, p < 0.001) to epithelial fraction (0.21 ± 0.08 to 0.43 ± 0.12, AUC = 0.94, p < 0.001).

conclusionVERDICT fIC showed clinical potential as a biomarker of epithelial cell density. KEY POINTS: Question Can VERDICT-MRI fIC provide a biologically interpretable, noninvasive imaging biomarker of epithelial cell density in the prostate? Findings VERDICT fIC showed stronger correlations with histological epithelial fraction, cell density, and epithelial density than both VERDICT-derived ADC and mpMRI ADC. Relevance statement These findings support in vivo VERDICT fIC as a noninvasive biomarker of prostate epithelial microstructure and show promise for wider clinical use, improving the detection rate of clinically significant PCa, reducing unnecessary biopsies, and allowing better risk stratification.

Indexed as

Magnetic Resonance ImagingMultiparametric Magnetic Resonance ImagingProstateProstatic NeoplasmsAgedHumansMaleMiddle AgedNeoplasm GradingProstatectomyBiomarkersDiffusion magnetic resonance imagingMultiparametric magnetic resonance imagingProstatectomyProstatic neoplasms

Identifiers

PMID42714773
PMCPMC13558491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.